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Identification of a minimal promoter sequence for the human
N -acetyltransferase Type I gene that binds AP-1 (activator protein 1)
and YY-1 (Yin and Yang 1)
Neville J. BUTCHER, Ajanthy ARULPRAGASAM, Catherine POPE and Rodney F. MINCHIN1
Centre for Medical Research, University of Western Australia, Nedlands, Western Australia, Australia, and Laboratory for Cancer Medicine, Western Australian Institute for Medical
Research, Royal Perth Hospital, Perth, Western Australia 6000, Australia

Human N-acetyltransferase Type I (NAT1) catalyses the acetylation of many aromatic amine and hydrazine compounds and it
has been implicated in the catabolism of folic acid. The enzyme
is widely expressed in the body, although there are considerable
differences in the level of activity between tissues. A search of
the mRNA databases revealed the presence of several NAT1 transcripts in human tissue that appear to be derived from different
promoters. Because little is known about NAT1 gene regulation,
the present study was undertaken to characterize one of the putative promoter sequences of the NAT1 gene located just upstream
of the coding region. We show with reverse-transcriptase PCR
that mRNA transcribed from this promoter (Promoter I) is present
in a variety of human cell-lines, but not in quiescent peripheral
blood mononuclear cells. Using deletion mutant constructs, we
identified a 20 bp sequence located 245 bases upstream of the

translation start site which was sufficient for basal NAT1 expression. It comprised an AP-1 (activator protein 1)-binding site,
flanked on either side by a TCATT motif. Mutational analysis
showed that the AP-1 site and the 3 TCATT sequence were necessary for gene expression, whereas the 5 TCATT appeared to attenuate promoter activity. Electromobility shift assays revealed two
specific bands made up by complexes of c-Fos/Fra, c-Jun, YY-1
(Yin and Yang 1) and possibly Oct-1. PMA treatment enhanced
expression from the NAT1 promoter via the AP-1-binding site.
Furthermore, in peripheral blood mononuclear cells, PMA increased endogenous NAT1 activity and induced mRNA expression from Promoter I, suggesting that it is functional in vivo.

INTRODUCTION

tively called this Promoter I. A second transcript derived from
ovarian adenocarcinoma cells (GenBank® accession number
BC013732) contains a 5 non-coding sequence that, when aligned
to the genomic sequence of 8p21.3–23.1, indicates the presence
of several introns in this region of the gene that extend 12 kb
upstream of the coding sequence. This transcript indicates that a
second promoter (Promoter II) for NAT1 exists further upstream.
Neither of these putative promoters have been characterized to
date.
In the present study, we have investigated the structure and
function of Promoter I and show that the transcript generated from
this regulatory region is present in a variety of human cell lines.
We identified a 20 bp sequence 245 bases upstream of the coding
region that contains an AP-1 (activator protein 1)-binding site and
is activated by PMA. The AP-1-binding site is flanked on either
side by a TCATT motif which have a role in gene expression.

In humans, the acetylation of primary arylamines and hydrazines
is catalysed by two cytoplasmic acetyltransferases (EC 2.3.1.5),
N-acetyltransferase Type I (NAT1) and NAT Type II (NAT2) (also
called arylamine N-acetyltransferases). The genes encoding these
proteins were first identified by Grant et al. [1,2], and both have
been mapped to chromosome 8p21.3–23.1 [3]. Sequencing of
NAT1 and NAT2 revealed a number of allelic variants that affect
activity of each gene in vivo [4,5]. This work provided a genetic
understanding of the long known polymorphism in NAT1 and
NAT2 activity [6–9].
NAT1 acetylates a number of exogenous substrates, as well as
the folate catabolite p-aminobenzoylglutamate [10,11]. Whereas
NAT1 is widely expressed in humans, there is a considerable
heterogeneity in the levels of expression between tissues [12].
Two NAT1 mRNAs submitted to GenBank are homologous to
the coding and 3 non-coding region of the genomic sequence,
but differ from each other at the 5 non-coding region. The first
mRNA (GenBank® accession number D90041) was isolated from
human liver [13] and has a 5 non-coding sequence identical
with that of the published genomic sequence, indicating a lack
of introns [2]. Several expressed sequence tags confirm the presence of this transcript in a variety of tissues. The predicted length
of the message determined by Northern blots [2] suggests that
the promoter of this NAT1 transcript resides approx. 250–300
bases upstream of the translational start site. We have tenta-

Key words: N-acetyltransferase, activator protein 1 (AP-1), gene
induction, promoter, transcription factor.

EXPERIMENTAL
Materials

All cell lines were originally obtained from the A. T. C. C.
(Rockville, MD, U.S.A.). Donor PBMCs (peripheral blood
mononuclear cells) were obtained by venipuncture and isolated
as described previously [9]. Restriction enzymes, dNTPs, Dual
Luciferase kit, Erase-A-Base kit, pRL-SV40 and pGL3-enhancer
vectors were obtained from Promega (Madison, WI, U.S.A.).

Abbreviations used: AP-1, activator protein 1, CREB, cAMP-response-element-binding protein; DMEM, Dulbecco’s modified Eagle’s medium; DTT,
dithiothreitol; EMSA, electrophoretic-mobility-shift assay; GM-CSF, granulocyte/macrophage colony-stimulating factor; NAT, N -acetyltransferase; NAT1MP, NAT1 minimal promoter; RT, reverse transcriptase; PBMC, peripheral blood mononuclear cell; YY-1, Yin and Yang 1.
1
To whom correspondence should be addressed (e-mail rminchin@receptor.pharm.uwa.edu.au).
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Oligonucleotides used in this study

Bases that differed from the NAT1-MP sequence are underlined. For the EMSA experiments, complementary oligonucleotides (not shown) were used to generate double-stranded oligonucleotides.
The non-specific oligonucleotide NS is from Naora et al. [17].
Oligonucleotide name

Sequence

Comment

PCR
NAT1-F
NAT1-R
FP1
FP2
FP3
FP4
RP1
97-F
M1-F
M2-F
M3-F
PGLprimer2

5 -GGGAAATTGAGTGGGTCAGG-3
5 -CCATGATCCCCTAAGCAAGG-3
5 -TAGCCATAATTAGCCTACTC-3
5 -GGGACTATTAACTGAACTTATGT-3
5 -ATCATTTGACTCATCATTTA-3
5 -AAATTGAGTGGGTCAGG-3
5 -AAGGTGAATCATGCCAGTGC-3
5 -CCCAAGCTTATCTTGATTTCCAGC-3
5 -CCCAAGCTTCCGATGTGACTCATCATTTAATCTTG-3
5 -CCCAAGCTTATCATTGCCGACTTCATTTAATCTTG-3
5 -CCCAAGCTTATCATTTGACTCAGCACTTCATCTTGATTTC-3
5 -CTTTATGTTTTTGGCGTCTTCCA-3
5 -TCACCCACACTGTGCCCATCTACGA-3
5 -CAGCGGAACCGCTCATTGCCAATGG-3

Forward primer for initial cloning of the NAT1 5 region
Reverse primer for initial cloning of the NAT1 5 region
Forward primer for mapping of transcription start site*
Forward primer for mapping of transcription start site*
Forward primer for mapping of transcription start site*
Forward primer for mapping of transcription start site*
Reverse primer for mapping of transcription start site
Forward primer for construction of pGL-97
Forward primer for construction of pGL-M1
Forward primer for construction of pGL-M2
Forward primer for construction of pGL-M3
Reverse primer for construction of pGL-97, pGL-M1, GL-M2
and pGL-M3
Forward primer for amplification of β-actin
Reverse primer for amplification of β-actin

5 -ATCATTTGACTCATCATTTA-3
5 -CCGATGGCCGACTGCACTTCT-3
5 -CGCTTGATGACTCAGCCGGAA-3
5 -CCGATGTGACTCATCATTTA-3
5 -ATCATTGCCGACTTCATTTA-3
5 -ATCATTTGACTCAGCACTTC-3

Wild-type NAT1 oligonucleotide
Non-specific sequence used as control
Consensus AP-1 oligo lacking both TCATT motifs
Mutations in 5 TCATT motif of NAT1-MP
Mutations in AP-1 like motif of NAT1-MP
Mutations in 3 TCATT motif of NAT1-MP

Actin-F
Actin-R
EMSA
NAT1-MP
NS
AP-1
M1
M2
M3
* See Figure 1 for location.

Primers and plasmid purification kits were purchased from
GeneWorks (Adelaide, Australia), and Rneasy kit was obtained
from Qiagen (Melbourne, Australia). Poly[d(I-C)] and High
Pure RNA Isolation Kits were supplied by Roche (Castle Hill,
Australia). RPMI 1640, DMEM (Dulbecco’s modified Eagle’s
medium), DH5α bacteria and T4 polynucleotide kinase were
obtained from Invitrogen (Melbourne, Australia), and antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, U.S.A.). G-25 minispin columns and pUC18 were purchased
from Amersham Pharmacia Biotech (Melbourne, Australia).
Fetal bovine serum was supplied by the Commonwealth Serum
Laboratories (Melbourne, Australia). All other chemicals were
obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Cell culture

All cell lines were cultured in RPMI 1640 (except PBMCs which
were cultured in DMEM), supplemented with 10 % fetal bovine
serum, 80 units/ml benzylpenicillin and 50 µg/ml gentamicin, at
37 ◦ C in an atmosphere of 5 % CO2 in air.

Amplification of NAT1 mRNA

Cytoplasmic RNA was isolated using a High Pure RNA Isolation
Kit or the Rneasy kit, and 0.5 µg of RNA was reverse transcribed with 15 units of avian myeloblastosis virus reverse transcriptase (RT), 5 mM MgC12 , 1 mM dNTPs, 1 units/µl rRNasin
ribonuclease inhibitor and 0.5 µg of oligo(dT)15 primer in buffer
(10 mM Tris/HCl, pH 8.8/50 mM KCl/0.1 % Triton X-100).
Reactions were incubated at 42 ◦ C for 30 min and then inactivated by heating at 98 ◦ C for 5 min. NAT1 cDNA was amplified
by PCR using the common reverse primer RP1 (Table 1),
which is located in the open reading frame of the NAT1 gene, and
the forward primers FP1-4 (Table 1), which are located at various
distances upstream of the NAT1 open reading frame (Figure 1).
PCR reactions were carried out in PCR buffer containing 5 µl
of cDNA mix, 2 mM MgCl2 , 0.5 unit of Taq DNA polymerase,
and 12.5 pmol of each primer in a final volume of 20 µl. Samples
were amplified using the following conditions: denaturation at
95 ◦ C for 5 min, followed by 30 cycles of 95 ◦ C for 30 s, 55 ◦ C
for 45 s and 72 ◦ C for 45 s. As a control, PCR reactions were also
performed to detect β-actin using primers Actin-F and Actin-R
(Table 1). PCR conditions were as described above, except the
annealing temperature was 58 ◦ C and the number of cycles 25.

Isolation of genomic fragment by PCR

The − 416 to + 1 region (relative to the translational start site)
of the human NAT1 gene was generated by PCR using human
genomic DNA and the primers NAT1-F and NAT1-R (Table 1).
This fragment was blunt-end ligated into the SmaI site of
pUC18 and sequenced by the dideoxynucleotide chain termination method. A 247 bp KpnI–EcoRI fragment from the plasmid
was then cloned into the multiple cloning site of the pGL3enhancer vector upstream of the firefly luciferase gene, creating
the pGL-247 construct.
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Promoter deletion constructs

A series of deletion mutants was generated from the pGL-247 construct using the Erase-A-Base system. In brief, the pGL-247
plasmid was linearized with SacI to generate exonuclease III
resistant 3 overhangs on each end. The 5 end of the NAT1 promoter fragment was then converted to an exonuclease III sensitive overhang by digestion with NheI. The resulting DNA was
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5 Untranslated region of the human NAT1 gene

The complete 441 bp sequence, originally reported by Blum et al. [2], is shown with the start codon at the 3 end. The 247 bp Kpn I–Eco RI fragment used in the present study (bold type) was
cloned into the pGL3-Enhancer vector to create pGL-247. A series of deletion mutants were then generated as outlined in the Experimental section. Progressively shorter clones (pGL-220, pGL-185,
pGL-144, pGL-117, pGL-97, pGL-83 and pGL-54) were selected and the locations of their 5 ends are shown in the Figure. The deletion constructs are named with numbers representing their
length from the 3 T of the Eco RI site. Also shown is a putative consensus initiator element (boxed) [16], as well as the position of the four forward primers (FP1–4, underlined) used to locate the
approximate position of the transcription start site.

phenol–chloroform extracted and then treated with exonuclease
II and S1 nuclease, according to the manufacturer’s instructions.
At 30 s intervals, the reaction was terminated, the DNA was
ethanol precipitated, redissolved in water and treated with Klenow
fragment. After religation, the resulting plasmids were used to
transform DH5α cells. Clones were isolated and sequenced, and
six constructs with promoter lengths of 54 bp (pGL-54), 83 bp
(pGL-83), 117 bp (pGL-117), 144 bp (pGL-144), 185 bp (pGL185) and 220 bp (pGL-220) were selected for use in transient
transfection assays (see Figure 1 for location of each fragment).
The pGL-97, pGL-M1, pGL-M2 and pGL-M3 constructs were
prepared by PCR using appropriate oligonucleotides containing
a HindIII site (97-F, M1-F, M2-F and M3-F respectively, see
Table 1) and the common reverse primer pGLprimer2 (Table 1).
The fragments generated were HindIII digested and cloned
into the HindIII site of pGL3-enhancer vector, purified from
DH5α clones and used for transfection experiments. DNA
concentrations were determined by a fluorimetric assay [14], and
all constructs were sequenced by the dideoxynucleotide chain
termination method.

Preparation of nuclear extracts

THP-1 cells (2.5 × 107 ) were harvested by centrifugation at
1000 g for 5 min, washed once with ice-cold PBS and resuspended in 600 µl of ice-cold lysis buffer [10 mM Hepes, pH 7.9/
1.5 mM MgCl2 /10 mM KCl/0.5 mM DTT (dithiothreitol)/
0.5 mM PMSF/2 µg/ml leupeptin/2 µg/ml pepstatin A]. On
ice, the cells were disrupted by passage through a 27-gauge needle.
The nuclei were collected by centrifugation in a microcentrifuge
at 15 000 g for 8 s. The supernatants were discarded and the cell
pellets resuspended in 70 µl of ice-cold extraction buffer (lysis
buffer containing 20 mM Hepes, pH 7.9, 420 mM KCl, 0.2 mM
EDTA and 25 % glycerol). After 30 min on ice, 50 µl of storage
buffer (20 mM Hepes, pH 7.9/0.5 mM DTT/0.2 mM EDTA/20 %
glycerol/0.5 mM PMSF/2 µg/ml leupeptin/2 µg/ml pepstatin A)
was added and the extracts centrifuged at 15 000 g for 10 min
(4 ◦ C). Supernatants were stored at − 20 ◦ C. Protein concentrations (usually 3–6 µg/µl) were determined by the Bradford
method [15], using BSA as a standard.

EMSA (electrophoretic-mobility-shift assay)
Transient expression of reporter constructs

Transient cell transfection using the DEAE-dextran method was
performed as follows. Transfection solutions were prepared using
0.5 µg of plasmid DNA, 0.1 µg of the co-reporter (pRL-SV40
containing the Renilla luciferase gene) and 0.5 mg/ml DEAEdextran in RPMI/20 mM Hepes buffer (RPMI/Hepes), pH 7.3.
The cells, at a density of 4 × 106 cells/ml, were treated for 90 min,
after which time they were washed twice with RPMI/Hepes and
the medium exchanged for RPMI-1640 containing 10 % fetal calf
serum. Cells were plated at 4.5 × 105 cells/ml and cultured for
48 h. They were then harvested and extracts prepared for the Dual
Luciferase Assay, according to the manufacturer’s instructions.
Renilla luciferase activities served to normalize firefly luciferase
activities, and all results are reported as means +
− S.E.M. for at
least three experiments.

Nuclear extracts (5 µg of protein) were incubated for 30 min at
22 ◦ C in binding buffer (2 % Ficoll 400/5 % glycerol/20 mM
Hepes, pH 7.9/50 mM KCl/1 mM EDTA/2.5 mM DTT) containing 0.5 µg of poly[d(I-C)] and 32 P-labelled oligonucleotide probe
(1 × 105 d.p.m.) in a final volume of 10 µl. Samples were then
resolved by electrophoresis on 5 % polyacrylamide gels at 200 V
in 0.25 × Tris/borate/EDTA buffer for 150 min at 4 ◦ C. Gels were
dried and placed on a phosphorimage screen for 12 h.
Oligonucleotides were purified by reverse-phase chromatography and freeze-dried. Double-stranded oligonucleotides were
prepared by heating both sense and anti-sense strands at 65 ◦ C
for 5 min before slowly cooling to 22 ◦ C. Oligonucleotides were
labelled using [γ -32 P]ATP (3000 Ci/mmol) and T4 polynucleotide kinase. Labelled probes were purified from unincorporated
[γ -32 P]ATP using MicroSpin G-25 columns.
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Figure 3

Approximate location of the NAT1 transcription start site

To determine the approximate location of the start site for message transcribed from Promoter I, a series of forward primers (FP1–FP4; Table 1) and a common reverse primer (RP1) was
used to amplify reverse-transcribed RNA isolated from Jurkat cells. Genomic DNA was used as
a positive control to illustrate the expected PCR products (right-hand panel). Amplification of
cDNA was only successful using FP1 and FP2 (left-hand panel). To ensure DNA contamination
did not interfere with the RT-PCR, RT was omitted from each of the amplification reactions
(middle panel).

Figure 2 RT-PCR for message transcribed from the putative NAT1
Promoter I
Cytosolic RNA from a variety of cell lines and PBMCs was reverse transcribed and then amplified
using primers FP2 and RP1 (Table 1). β-Actin was also amplified as a positive control (lower
panels). To ensure there was no DNA contamination, amplification was also performed on
samples where RT was omitted from the reaction.

For competition assays, unlabelled oligonucleotides were
added to the binding reactions at a 100-fold molar excess 10 min
prior to the addition of radiolabelled probe. For antibody supershift analysis, binding reactions were incubated with 1 µg of
antibody for 3 h at 4 ◦ C before the addition of probe.

RESULTS
Identification of NAT1 mRNA in human cells

We used RT-PCR to detect NAT1 message transcribed from Promoter I (Figure 2). All cells except quiescent PBMCs expressed
the transcript, although the amount of message appeared to vary
between cell lines. Although the RT-PCR was not performed under
quantitative conditions, there were clear qualitative differences
between the various cell lines. The highest level of transcript was
seen in breast carcinoma MCF7 cells and T-lymphotropic Jurkat
cells. NAT1 cDNA from PBMCs did not amplify, despite amplification of β-actin gene.

Location of the NAT1 transcription start site

We attempted to locate the transcription start site for NAT1
mRNA by 5 -RACE (rapid amplication of cDNA ends), but were
unsuccessful, possibly due to its low copy number. We then used
a series of primers that hybridized upstream of the NAT1-coding
sequence and RT-PCR to identify the approximate region of the
transcription start site (Figure 3). The location of the primers used
is shown in Figure 1. The results show that the NAT1 transcript
commenced somewhere between the primers FP2 and FP3 or
between − 161 and − 244 bases upstream of the translation start
site, which is consistent with the size of human NAT1 mRNA
reported by Ohsaka and Deguchi [13]. There is no evidence of a
TATA box in this region, although at least one consensus initiator
element (YYANWYY) [16] is present, located at − 219 to − 226
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Figure 4

Location of promoter elements using deletion mutants

A series of deletion constructs was transiently transfected along with the co-reporter plasmid
pRL-SV40 (internal control) into THP-1 cells. After 48 h, cell lysates were prepared for dual
luciferase assays. Activity is expressed as relative luciferase activity (means +
− S.E.M., n = 3).
Asterisk indicates results significantly less (P < 0.05) than the full-length promoter (one-way
analysis of variance with Dunnett’s post-test comparison).

(Figure 1). Based on these findings, we investigated a 247 bp
KpnI–EcoRI fragment for promoter activity.

Identification of Promoter I

A series of deletion mutants of the NAT1 5 non-coding region
( − 147 bp to − 394 bp relative to the transcription start site)
fused to a luciferase reporter gene was examined for basal promoter activity by transient transfection in the monocytic cell line
THP-1 (Figure 4). The longest sequence (pGL-247, where the
number represents the number of base pairs 5 of the EcoRI
site located in the 5 UTR; see Figure 1) produced a 3- to 4-fold
increase in promoter activity compared with the pGL-enhancer
vector. Activity was seen in all constructs containing at least
the first 117 bp. Similar results were seen with CEM (T-cell
leukaemia), HT-29 (colon carcinoma), MCF-7 (breast carcinoma)
and Jurkat cells (results not shown). These results identify
a promoter sequence (Promoter I, 5 -ATCATTTGACTCATCATTTA-3 ) between − 245 and − 264 bases upstream of the
coding region (shown as FP3 in Figure 1). Putative transcription
factor binding sites are present within Promoter I, in particular
an AP-1 consensus sequence (TGACTCA) and two TCATT
motifs that have been identified in the regulatory sequences of
several genes including the GM-CSF (granulocyte/macrophage
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for this study. The faster migrating specific complex (band I)
was significantly more intense than band II and appeared to
comprise multiple complexes with similar electromobilities. The
formation of both bands were inhibited by the AP-1 consensus
oligonucleotide, as well as M1 and M3 which have base changes in
each of the flanking TCATT motifs, but not in the AP-1 sequence.
M2, which has mutations in the AP-1-binding site only, had a
slight effect on the formation of both bands. Collectively, these
results suggest that the faster migrating complex was formed
primarily through the interaction of nuclear proteins with the AP1-binding site. The slower migrating complex is possibly formed
by the binding of additional protein(s) to adjacent bases.

Identification of binding proteins in THP-1 nuclear extracts

The presence of the AP-1 consensus sequence in Promoter I
suggested that transcription factors of the bZIP family bind to
this sequence and possibly regulate NAT1 basal expression. We
examined the binding of a number of transcription factors by
supershift assays using the Promoter I oligonucleotide as a probe
(Figure 5B). The anti-c-Jun antibody shifted band II and decreased
the intensity of band I. In contrast, the anti-Fos/Fra antibody,
which recognizes c-Fos, Fos B, Fra-1 and Fra-2, completely
shifted band I. Antibodies directed against NF-E2 (nuclear factor
E2), Sp1, CREB1 (cAMP-response-element-binding protein 1),
c-rel, NF-κB (nuclear factor κB) and EGR-1 (early growth response gene product 1) had little or no effect. Anti-Oct-1 antibodies
selectively disrupted band II, whereas antibodies directed against
YY-1 (Yin and Yang 1) completely abrogated the formation of
both complexes.

Transcriptional activity of mutant Promoter I
Figure 5

EMSAs with the Promoter I probe and THP-1 nuclear extracts

(A) Labelled oligonucleotide and nuclear extracts were resolved on 5 % polyacrylamide gels to
show two specific bands (I and II) that were competed with 100-fold excess probe (NAT1-MP),
but not with the non-specific oligonucleotide (NS). Both band I and band II were competed
with the consensus AP-1 oligonucleotide, as well as the M1 and M3 oligonucleotides, which
contain mutations in the 5 and 3 TCATT sequence respectively. Only band II was competed
with M2 oligonucleotide which contained mutations in the AP-1-binding site. The sequence
of each oligonucleotide used is shown in Table 1. (B) Supershifted EMSAs with the NAT1-MP
probe and THP-1 nuclear extracts. Nuclear protein (5 µg) was incubated with antibody (1 µg)
for 3 h at 4 ◦ C before the addition of radiolabelled probe. The complexes were then resolved
on 5 % polyacrylamide gels. The two specific bands identified in (A) are shown. Supershifted
bands are indicated by arrow heads.

colony-stimulating factor) gene [17–22], interleukin-5 gene
[17,23], CD35 gene [24], involucrin gene [25], glucagon
gene [26], papillomavirus E6–E7 gene [27] and the angiotensin II
type 1a receptor gene [28].

Binding of nuclear proteins to Promoter I

EMSAs were performed with nuclear extracts from THP-1 cells
and the Promoter I oligonucleotide as a probe (Figure 5A).
Two specific bands (I and II) were identified that could be
competed with 100-fold molar excess of unlabelled probe, but
not by a non-specific oligonucleotide (Figure 5A). There were
three faster migrating bands that were also inhibited by NAT1MP (NAT1 minimal promoter). However, since these bands
were also partially or completely inhibited by the non-specific
oligonucleotide, they were considered as non-specific bands

The mutant sequences (M1, M2 and M3) used for competition
assays in Figure 5(A) were engineered into pGL-117 to produce
the reporter plasmids pGL-M1, pGL-M2 and pGL-M3. These
constructs were then used for transient transfection assays in
THP-1, Jurkat and HT-29 cells (Figure 6). When compared with
the wild-type sequence (pGL-117), mutations in the 5 TCATT
sequence (pGL-M1) enhanced activity by 2- to 3-fold in each cell
line. In contrast, mutations in the AP-1-binding site (pGL-M2)
decreased gene expression to that seen with the pGL-enhancer
construct. Similarly, mutation of the 3 TCATT sequence (pGLM3) also resulted in a significant decrease in promoter activity.
Thus both the AP-1-binding site and 3 TCATT motif are required
for optimum activity of Promoter I. In contrast, the 5 TCATT
motif appeared to act as an attenuator of activity.

Activation of AP-1 and NAT1 expression by PMA

To determine whether Promoter I responds to AP-1 activation, the
effect of PMA treatment on luciferase expression from the pGL117, pGL-M1, pGL-M2, pGL-M3 and pGL-SV40 constructs was
investigated in Jurkat cells. For these experiments Renilla control
vector was not included, because the promoter (SV40) for this
construct is inducible by PMA. Instead, cells were transfected
with each construct and then divided into aliquots after 24 h. One
aliquot of cells was treated with PMA and the second was treated
with vehicle. Thus transfection efficiency within each experiment
was constant. As a positive control for PMA activation, the pGLSV40 construct was also included and showed a 6-fold increase in
luciferase expression compared with untreated cells (Figure 7A).
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Figure 7 Effect of PMA on Promoter I activity and endogenous NAT1
expression

Figure 6

Effect of mutations in NAT1-MP on gene expression

Mutations were introduced into the pGL-117 reporter construct to alter the three motifs identified
in the NAT1-MP sequence. Each construct was then transiently transfected into THP-1, Jurkat
or HT-29 cells. Luciferase activities were measured 48 h later and are expressed relative to the
Renilla luciferase activity. The results are expressed as the means +
− S.E.M. for three experiments.
Asterisk indicates results significantly different (P < 0.05) to pGL-117 (one-way analysis of
variance with Dunnett’s post-test comparison).

PMA enhanced expression from both pGL-117 and pGL-M1, but
had little or no effect on pGL-M2 or pGL-M3, consistent with
the AP-1-binding site and the 3 TCATT motif being essential for
gene expression.
We also examined the effects of PMA on endogenous NAT1
activity in PBMC, the only cell type examined where there was
no evidence of transcript produced from Promoter I (Figure 2).
PMA significantly increased the activity of NAT1 from 10.3 +
− 0.7
+
to 16.0 +
0.2
nmol/min
per
mg
of
protein
(mean
S.E.M.,
n
= 3,
−
−
P < 0.05) using p-aminobenzoic acid as substrate. RT-PCR
showed NAT1 mRNA was generated in cells from Promoter I following PMA treatment, but not in untreated cells (Figure 7B), consistent with results shown in Figure 2. This could not be accounted
for by DNA contamination, as there was no amplification in
the absence of reverse transcriptase. Futhermore, the lack of a
product for NAT1 in the untreated cells was not the result of little
or no RNA, since β-actin cDNA amplified from these samples
produced the predicted PCR product.

DISCUSSION

Human NAT1 is found in most tissues, although its level of activity
varies markedly [12]. The genetic regulation of the NAT1 gene
has not been reported to date and there has been little study of
its genomic organization. In the present study, we have identified
a transcript that is generated from a regulatory region located
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(A) Jurkat cells were transiently transfected with pGL-117 and the respective mutant constructs
as described in Figure 6. After 24 h, the transfected cells were divided in two and treated
with PMA (100 ng/ml) or vehicle (0.1 % DMSO). Luciferase activity was measured 24 h later.
The results are expressed as the fold increase in activity compared with vehicle-treated cells
(means +
− S.E.M., n = 3). Asterisk indicates results significantly different (P < 0.05) than pGL117 (one-way analysis of variance with Dunnett’s post-test comparison). (B) PBMCs were treated
with PMA (100 ng/ml) for 24 h, following which cytosolic RNA was isolated and amplified by
RT-PCR to detect the presence or absence of mRNA transcribed from Promoter I (lanes 5–8).
To control for the integrity of the isolated RNA, β-actin was amplified from each RNA sample
(lanes 1–4). Each PCR reaction was also performed using RNA without RT to ensure a lack of
DNA contamination (lanes 1, 3, 5 and 7).

245 bases upstream of the translation start site. The transcript
does not appear to contain introns and it is expressed in a range
of human cell lines, but not in quiescent PMBCs. The promoter
was mapped to a 20-bp fragment that contained an AP-1-like
binding site, flanked on either side by a TCATT motif, and it was
functional in several different human cell lines. Using mutagenesis
and transient transfection assays, we found that both the AP-1
site and the 3 TCATT sequence were essential for gene expression, whereas the 5 TCATT appeared to act as an attenuator of
promoter activity. We also identified several transcription factors,
in particular members of the Fos/Fra family, capable of binding to
this region of the gene. Antibodies to YY-1 and Oct-1 inhibited one
or both of the specific complexes formed when nuclear extracts
were incubated with the Promoter I oligonucleotide, suggesting
that a complex of proteins bind to this sequence.
Promoter I is located 20 bases upstream of a putative consensus
initiator element (Figure 1) that lies within the region of the transcription start site (Figure 3). The promoter is structurally similar
to the rat glucagon gene promoter which contains a cAMP response element, flanked on either side by the TCATT repeat
[26]. In the glucagon promoter, the flanking sequences are involved in the binding of accessory proteins as a complex with
CREB, and the 3 TCATT sequence attenuates stimulation of the
promoter by protein kinase A. A similar CRE-TCATT motif is
present in the VGF (vaccinia virus growth factor) gene promoter,
although its role is yet to be fully defined [29]. The TCATT motif
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has also been found in the GM-CSF promoter, as described by
several investigators [17–22], where it binds YY-1 [22]. YY-1
can display either activator or repressor activity depending upon
the context of the promoter [22]. For some genes, YY-1 can
suppress promoter activity, whereas for others it has been shown to
activate transcription. Antibodies to YY-1 abrogated the specific
interaction of nuclear proteins with the NAT1 promoter I, a finding
similar to that reported for the GM-CSF promoter [22].
PMA treatment induced gene expression from Promoter I,
which is consistent with a central role for the AP-1-binding site.
Interestingly, the pGL-M3 construct, which has an intact AP-1binding site but lacks the 3 TCATT motif, did not respond to
PMA, suggesting that both motifs form a transcriptional complex
that regulates promoter activity. The mRNA transcribed from
Promoter I was present in a variety of cell lines, but not in
quiescent PBMCs. PMA stimulation of PBMCs, which promotes
cell proliferation, not only induced endogenous NAT1 activity,
but also induced transcription from Promoter I. Although further
work is required to fully understand the role of this region of the
NAT1 gene, it is possible that it is functional during the cell cycle
or following stimuli that activate AP-1.
There has been little information about the regulation of the Nacetyltransferases published to date. Estrada-Rodgers et al. [30]
have identified several putative regulatory elements, including a
hormone-responsive element at − 561, upstream of the mouse
homologue Nat2∗ . However, neither the TATA boxes nor the
putative hormone-responsive element are evident in the human
gene. A sequence similar to the human Promoter I described here
is present in the mouse gene at − 239 [30]. A more recent study by
Mitchell and Warshawsky [31] examined regions of the NAT1 and
NAT2 genes as far upstream as 1522 bases and reported that both
genes were inducible by substrates selective for each enzyme. No
specific sequence that endows inducibility was identified, and the
activity of the different upstream regions in the absence of inducer
was not reported. Nevertheless, both of these studies, along with
the results of the present study, suggest that the regulation of
NAT1 may be a complex process that responds to several different
external stimuli.
In conclusion, the present study has identified a regulatory
region of the human NAT1 gene with several consensus transcription factor binding sites. A number of studies have implied that
NAT1 has a role in cells in addition to the acetylation of exogenous
arylamine substrates [11,32–34]. The similarity of Promoter I with
those from other functionally unrelated genes further supports this
suggestion.
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